Vero Biotech
Vero Biotech is an Atlanta-based commercial-stage medical device company that develops and commercializes the GENOSYL Delivery System, the first and only FDA-approved tankless inhaled nitric oxide delivery platform for acute-care hospitals, NICUs, surgical suites, MRI, and inter-hospital transport. It serves U.S. hospitals via direct enterprise sales and Premier Inc. GPO.
- Company typePrivate
- Founded2019
- HeadquartersAtlanta, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Vero Biotech does
Vero Biotech, Inc. is an Atlanta, Georgia-based commercial-stage biopharmaceutical / medical device company that develops and commercializes the GENOSYL Delivery System (DS), the first and only FDA-approved tankless inhaled nitric oxide (iNO) delivery platform. Founded in 2006 (formerly GeNO LLC) and operating as a privately held, venture-backed business with 101-250 employees, the company targets acute-care hospitals, neonatal intensive care units, surgical suites, MRI environments, and inter-hospital transport services. Its flagship product addresses persistent pulmonary hypertension of the newborn (PPHN) and other hypoxic respiratory failure conditions, serving an addressable patient pool of roughly 100,000 neonates annually in the U.S. alone.
The GENOSYL DS platform replaces traditional large compressed-gas nitric oxide cylinders with a compact, 16 oz disposable cassette that generates iNO on demand at the bedside, paired with a proprietary Smart Feedback System that samples iNO at the patient to maintain precise dose control independent of ventilator settings or flow changes. The device is MRI-conditional up to 3.0 Tesla, FAA-tested for ground, fixed-wing, and rotary-wing transport, and is the only system FDA-approved for low-flow rebreathing anesthesia with major anesthesia machines (GE Aisys, Drager Fabius, Getinge Flow-i). Three product generations have received FDA approval across acute care (2019, 2023), MRI/inter-hospital transport (2020), and rebreathing anesthesia in the surgical suite (2023, 2025). A redundant backup console and automatic cassette transition are designed to minimize clinical interruption. The supporting ecosystem includes the VITA Information Transfer & Analytics web platform, the VERO Knowledge Center for clinician training, and Partnership365, a 24/7/365 service program staffed by registered respiratory therapists.
Vero generates revenue primarily through capital sales of GENOSYL DS hardware to acute-care hospitals, supplemented by recurring single-use disposable cassette consumption. Go-to-market is a direct enterprise field-sales motion targeting hospital procurement, respiratory therapy, and anesthesiology departments, augmented by a group purchasing organization channel via Premier Inc., which provides access to approximately 4,400 U.S. hospitals and 250,000 providers. Pricing is quote-based and not publicly disclosed. The company has raised cumulative disclosed funding of roughly $245M+ from 2021-2024 across equity (Runway Growth Capital, MVM Partners, Petrichor) and a $65M debt facility, and has been recognized with the AARC Zenith Award (2024), Premier's Technological Breakthrough designation (2023), and the Georgia Bio Golden Helix Innovation Award (2022).
Vero Biotech firmographics
Firmographics- Name
- Vero Biotech
- Legal name
- Vero Biotech, Inc.
- Website
- https://vero-biotech.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Vero Biotech is an Atlanta-based commercial-stage medical device company that develops and commercializes the GENOSYL Delivery System, the first and only FDA-approved tankless inhaled nitric oxide delivery platform for acute-care hospitals, NICUs, surgical suites, MRI, and inter-hospital transport. It serves U.S. hospitals via direct enterprise sales and Premier Inc. GPO.
- Ownership category
- akta.pro rank
Vero Biotech industry classification
Industry- Product category
- Respiratory Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)
Keywords
Where Vero Biotech is headquartered
LocationHeadquarters
- HQ city
- Atlanta
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Vero Biotech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations
Revenue model
- GENOSYL Delivery System Sales: Commercial-stage medical device company generating revenue from sale of GENOSYL DS hardware and disposable cassettes to acute care hospitals. Device sold to hospitals for use in ICU, transport, MRI, and surgical suite settings. Cassettes are single-use disposables requiring ongoing repurchase.
- GENOSYL DS Commercialization: Revenue generated through commercialization of FDA-approved GENOSYL Delivery System for treating severe pulmonary hypertension in hospitals. Series E funding from MVM Partners specifically supporting growth and market adoption.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Vero Biotech product offering
Product offeringCore offering
Vero Biotech manufactures and commercializes the GENOSYL Delivery System (DS), the first and only FDA-approved tankless inhaled nitric oxide (iNO) delivery system. The system generates iNO at the bedside using a patented disposable cassette, eliminating the need for large compressed gas tanks, and is approved for use across ICU, inter-hospital transport, MRI, and low-flow anesthesia settings. Revenue is generated through sales of the GENOSYL DS hardware to acute care hospitals and ongoing purchases of single-use cassettes.
Product overview
VERO Biotech offers a focused product portfolio anchored by the GENOSYL Delivery System (DS), a proprietary tankless inhaled nitric oxide (iNO) delivery system that is the first and only FDA-approved tankless system in its category. The portfolio consists of the GENOSYL DS hardware (available in multiple generations), the GENOSYL therapeutic gas cassette as a single-use consumable, the VITA Information Transfer & Analytics web platform for clinician data access, and the Partnership365 support program staffed by registered respiratory therapists. The system is designed for use across multiple care settings — ICU, inter-hospital transport, MRI suites, and low-flow anesthesia — with a Smart Feedback System for dose precision and built-in redundant backup. The VERO Knowledge Center provides on-demand training and education resources.
Differentiator
Problem solved
Functional benefit
Brands
- GENOSYL: The GENOSYL Delivery System (DS) is VERO Biotech's flagship product - a tankless, portable inhaled nitric oxide (iNO) delivery system for treating pulmonary hypertension and hypoxic respiratory failure in neonates.
- VITA
- Partnership365
Products and services
- GENOSYL Delivery System (DS) FDA-approved tankless inhaled nitric oxide (iNO) delivery system that generates and delivers iNO at the bedside using a disposable cassette. Features a Smart Feedback System for precise dosing, redundant backup console, and is approved for use in ICU, ground/fixed-wing/rotary-wing transport, MRI Suite, and low-flow anesthesia environments. Sold to acute care hospitals and health systems.
- GENOSYL DS Cassette A compact, 16 oz single-use, disposable cassette that stores at the bedside and generates inhaled nitric oxide on demand using patented technology. Eliminates tank management and reprocessing; automatic cassette transition ensures continuous, uninterrupted dosing. Sold as a recurring consumable to GENOSYL DS customers.
- GENOSYL (nitric oxide) gas, for inhalation Inhaled nitric oxide therapeutic gas indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in conjunction with ventilatory support and other appropriate agents.
- VITA Information Transfer & Analytics Web-based platform providing information transfer and analytics capabilities for GENOSYL DS users. Clinicians log in to access data related to the delivery system, with an associated mobile app (app.vita.vero-biotech.com) for on-the-go access.
- Partnership365 Service and Support 24/7/365 support program connecting customers with experienced registered respiratory therapists (10+ years bedside experience) for training, troubleshooting, clinical support, medical information, inventory management, and technical support. Includes on-demand training and education via the VERO Knowledge Center.
Quantifiable outcome
- Setup time reduced to less than 2 minutes
- +3 more outcomes
Companies that use Vero Biotech
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles4 records
Vero Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Vero Biotech partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Premier Inc.corePremier is a leading healthcare improvement company uniting approximately 4,400 U.S. hospitals and 250,000 other providers. VERO Biotech recognized as Innovative Supplier at Premier's Annual Supplier Innovation Celebration and Breakthroughs Conference.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Vero Biotech competitors and assessment
Company assessmentEmerging players
- Vapotherm: Vapotherm delivers respiratory gas therapy (high-velocity nasal insufflation) to neonatal and adult patients in acute care settings. Addresses overlapping NICU/respiratory customer base with a different delivery modality but competes for similar hospital respiratory therapy budgets.
Broad incumbents
- Becton Dickinson (BD): BD is a major medical device manufacturer with broad hospital drug delivery, infusion, and medication management offerings. Competes broadly for hospital formulary and connected therapeutics spend with comparable enterprise sales motion to acute care customers.
- Masimo: Masimo offers patient monitoring and connected care platforms in the hospital setting, comparable to Vero's VITA Information Transfer & Analytics platform and Smart Feedback System. Operates in adjacent categories (monitoring vs. delivery) with overlapping hospital customers.
- ICU Medical: ICU Medical manufactures drug delivery and infusion systems for acute care hospitals, overlapping with Vero's smart drug delivery and clinical workflow integration capabilities. Comparable customer base (hospital ICUs) and adjacent product category (connected therapeutic delivery).
Others
- Getinge: Getinge's Flow-i anesthesia machine is one of the platforms certified for use with GENOSYL DS. Functions as a complementary vendor in the same surgical suite setting rather than a competitor, but is a relevant comparable for acute care hospital equipment peers.
- Drägerwerk: Dräger manufactures anesthesia machines (Fabius) and ventilators that GENOSYL DS integrates with for low-flow rebreathing anesthesia. They are a key interoperability partner rather than direct competitor, but operate in the same ICU/OR acute care environment.
- GE HealthCare: GE HealthCare's Aisys anesthesia machine is one of the platforms GENOSYL DS integrates with for low-flow anesthesia. Operates as a complementary equipment vendor in the same OR acute care environment rather than a direct iNO competitor.
- Inogen: Inogen specializes in portable respiratory gas delivery (oxygen concentrators) for respiratory patients. Functions as an adjacent respiratory therapy company with a hospital and home-care presence, indirectly comparable as a respiratory drug/gas delivery business.
Direct peers
- Beyond Air: Beyond Air developed the LungFit PH, a tankless inhaled nitric oxide delivery system that received FDA approval in 2024. Directly competes with GENOSYL DS in the same PPHN indication with a similar portable, on-demand NO generation approach.
- Mallinckrodt Pharmaceuticals: Mallinckrodt markets INOmax (inhaled nitric oxide), the established tank-based iNO delivery system that is the primary competitor to Vero Biotech's GENOSYL DS in U.S. hospitals. Directly comparable product category, same indication (PPHN, hypoxic respiratory failure), and overlapping hospital customer base.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Vero Biotech social profiles
Digital presenceVero Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vero Biotech leadership team
Management profileNumber of profiles
Profiles4 records
Vero Biotech funding detail
Funding detailFunding overview
Funding rounds8 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vero Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vero Biotech
What does Vero Biotech do?
Vero Biotech manufactures and commercializes the GENOSYL Delivery System (DS), the first and only FDA-approved tankless inhaled nitric oxide (iNO) delivery system. The system generates iNO at the bedside using a patented disposable cassette, eliminating the need for large compressed gas tanks, and is approved for use across ICU, inter-hospital transport, MRI, and low-flow anesthesia settings. Revenue is generated through sales of the GENOSYL DS hardware to acute care hospitals and ongoing purchases of single-use cassettes.
Is Vero Biotech a public or private company?
Vero Biotech is a private company. It is classified as venture growth investor backed and is currently operating.
When was Vero Biotech founded?
Vero Biotech was founded in 2019. It employs 101 to 250 people.
Where is Vero Biotech based?
Vero Biotech is headquartered in Atlanta, United States, in the North America region.
How does Vero Biotech make money?
Two revenue lines are on record. GENOSYL Delivery System Sales are the primary driver. The others are GENOSYL DS Commercialization.
Who are Vero Biotech's main competitors?
Vapotherm is listed as an emerging player. Broad incumbents are Becton Dickinson (BD), Masimo and ICU Medical. Others are Getinge, Drägerwerk, GE HealthCare and Inogen. Direct peers are Beyond Air and Mallinckrodt Pharmaceuticals.
Does Vero Biotech have an API?
No public API is recorded for Vero Biotech.
What industry is Vero Biotech in?
Vero Biotech's product category is Respiratory Medical Devices. Its primary akta.pro industry code is HLACAFAL, Connected Therapeutics & Smart Drug Delivery Monitoring. Its NAICS code is 334510 and its SIC code is 3845.